Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)106.56
  • Today's Change-4.03 / -3.64%
  • Shares traded3.96m
  • 1 Year change-27.47%
  • Beta1.6203
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

  • Revenue in USD (TTM)6.85bn
  • Net income in USD-4.71bn
  • Incorporated2016
  • Employees5.60k
  • Location
    Moderna Inc200 Technology SqCambridge 02139-3578United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ICON PLC8.12bn612.34m27.18bn41.10k44.522.9422.683.357.407.4098.17112.020.4752--2.99197,571.203.593.934.284.8029.6628.917.557.37--3.150.2901--4.8925.6221.1813.6723.79--
Biogen Inc9.84bn1.16bn31.45bn7.57k27.112.1218.993.207.987.9867.67102.140.38271.314.641,299,287.004.5212.535.2014.8374.2481.8411.8126.931.263.860.31920.00-3.32-6.07-61.89-23.58-18.87--
DuPont de Nemours Inc12.07bn494.00m31.95bn24.00k73.771.3619.012.651.040.925626.7756.450.3023.504.94502,833.301.330.37091.480.46835.0835.694.421.971.736.610.2398414.03-7.29-11.79-51.1911.24-30.66-20.59
Gartner Inc5.91bn882.47m37.49bn20.24k43.4555.3434.926.3511.0711.0774.138.690.7805--3.68291,888.9011.668.2422.7414.7667.7867.5514.9412.20--12.010.7832--7.878.249.2449.78-4.06--
Moderna Inc6.85bn-4.71bn42.34bn5.60k--3.05--6.18-12.39-12.3917.6836.270.30938.156.011,222,857.00-21.2920.95-25.9429.5131.47---68.8432.103.36--0.03990.00-64.45119.28-156.37--46.22--
Iqvia Holdings Inc14.98bn1.36bn45.84bn87.00k34.617.5018.463.067.307.3080.4233.670.5761--4.76172,229.905.223.246.804.0734.9634.329.066.03--3.240.69110.003.987.5524.4743.397.17--
Data as of Mar 28 2024. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

37.66%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Dec 202345.65m11.95%
The Vanguard Group, Inc.as of 31 Dec 202332.51m8.51%
BlackRock Fund Advisorsas of 31 Dec 202316.97m4.44%
SSgA Funds Management, Inc.as of 31 Dec 202314.62m3.83%
Th�l�me Partners LLPas of 31 Dec 20237.35m1.92%
Wellington Management Co. LLPas of 31 Dec 20237.23m1.89%
Geode Capital Management LLCas of 31 Dec 20236.55m1.71%
Fidelity Management & Research Co. LLCas of 31 Dec 20235.83m1.53%
Capital Research & Management Co. (World Investors)as of 31 Dec 20233.63m0.95%
Manulife Investment Management (US) LLCas of 31 Dec 20233.54m0.93%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.